

Flu B, and RSV from a single patient sample. **Beckman Coulter Diagnostics** launched several new COVID-related antibody tests and an automated antigen test to help make higher-volume mass testing possible. As of March 1, 2021, our operating companies have collectively enabled or produced approximately 100 million COVID-19-related diagnostic tests.

**Cytiva** and **Pall Biotech** have contributed significantly to the development and production of COVID-19 vaccines and treatments around the world, helping to accelerate manufacturing on a massive scale under intense time pressure. As of March 1, 2021, we are involved in most vaccine and therapeutic projects underway globally, including all vaccines in the U.S. that have received FDA Emergency Use Authorization or are in late-stage clinical trials. Our teams' efforts will continue to directly impact the lives of billions of people around the world, as there is still much more work to be done to tackle this global health crisis.

## A Transformational Acquisition

Our acquisition of **Cytiva** is one of several, strategic portfolio moves we have made during the last few years that accelerated our evolution into a higher-growth, innovation-driven company. With the addition of **Cytiva**, we doubled our annual revenue in the highly attractive biopharmaceutical end-market, which now represents more than 50% of our Life Sciences platform's annual revenue. With a more comprehensive offering across the entire bioproduction workflow, we are better able to support our customers who are working to deliver more life-improving drugs faster and at a lower cost—an endeavor made even more urgent by today's global health crisis.

The caliber of talent at **Cytiva** is the business' greatest asset. This highly innovative, passionate team has been working to solve its customers' toughest

biologics development and production challenges for over thirty years. In 2020, **Cytiva** achieved more than 25% core revenue growth and over \$4 billion in revenue. We could not be more pleased with **Cytiva's** early results and are excited about what we can achieve together over the next thirty years and beyond.

## Investing for Growth

Our strong margin performance and cash flow generation in 2020 enabled us to strengthen our competitive advantage through high-impact growth investments across **Danaher**. We expanded production capacity at **Cepheid**, **Cytiva** and **Pall** to support increasing demand for COVID-related testing and treatments, while paving the way for sustainable long-term growth.

Ongoing organic investments in research and development came to fruition in 2020 with several breakthrough product launches across our portfolio. **SCIEX's** new 7500 System is the most sensitive Triple Quad mass spectrometer on the market, helping scientists detect and quantify analytes at previously undetectable levels. The **Videojet** 1280 Continuous Inkjet printer was designed with simplicity and reliability in mind, providing customers with a high-quality printer that is easy to use and minimizes disruptive downtime. And **Leica Biosystems'** next-generation digital pathology scanner, the **Aperio GT 450 DX**, enables pathologists to evaluate tissue samples remotely without compromising quality or consistency—a crucial capability during the pandemic.

Inorganic investments are also a key component of our growth strategy. **Aquatic Informatics**—a leading water-focused software provider—joined our Water Quality platform in 2020, bringing data analytics solutions to improve customer workflow and cost efficiencies. Since 2019, we have acquired ten